218 related articles for article (PubMed ID: 34357559)
1. The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
Diabetes Ther; 2021 Sep; 12(9):2499-2515. PubMed ID: 34357559
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial.
Katakami N; Mita T; Maeda N; Sato Y; Watada H; Shimomura I;
Cardiovasc Diabetol; 2022 Feb; 21(1):19. PubMed ID: 35123483
[TBL] [Abstract][Full Text] [Related]
3. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
Cardiovasc Diabetol; 2020 Jul; 19(1):110. PubMed ID: 32646498
[TBL] [Abstract][Full Text] [Related]
4. The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis.
Mita T; Katakami N; Shiraiwa T; Yoshii H; Gosho M; Ishii H; Shimomura I; Watada H;
Diabetes Ther; 2017 Jun; 8(3):693-704. PubMed ID: 28516377
[TBL] [Abstract][Full Text] [Related]
5. Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.
Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Kurozumi A; Hatazaki M; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Kato K; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
Cardiovasc Diabetol; 2023 Jun; 22(1):143. PubMed ID: 37349722
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2017 Oct; 19(10):1397-1407. PubMed ID: 28371205
[TBL] [Abstract][Full Text] [Related]
7. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
[TBL] [Abstract][Full Text] [Related]
8. Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study.
Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ohashi M; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
Diabetes Ther; 2017 Oct; 8(5):999-1013. PubMed ID: 28864997
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes.
Suzuki K; Mitsuma Y; Sato T; Anraku T; Hatta M
J Clin Med Res; 2016 Nov; 8(11):805-814. PubMed ID: 27738482
[TBL] [Abstract][Full Text] [Related]
10. Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients.
Otagaki M; Matsumura K; Kin H; Fujii K; Shibutani H; Matsumoto H; Takahashi H; Park H; Yamamoto Y; Sugiura T; Shiojima I
Cardiovasc Drugs Ther; 2019 Aug; 33(4):435-442. PubMed ID: 31321581
[TBL] [Abstract][Full Text] [Related]
11. Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study).
Ishii H; Nakajima H; Kamei N; Niiya T; Hiyoshi T; Hiramori Y; Ohtsu S; Noto T; Shimono D
Diabetes Ther; 2020 Dec; 11(12):2959-2977. PubMed ID: 33057967
[TBL] [Abstract][Full Text] [Related]
12. Effects of Switching From Another Sodium-Glucose Cotransporter 2 Inhibitor to Tofogliflozin on Nocturia in Patients With Type 2 Diabetes.
Inoue S; Yasuda H; Yoshida K; Mori K; Ogawa K; Yokotsuka Y; Okamoto H
Cureus; 2024 Apr; 16(4):e59411. PubMed ID: 38826603
[TBL] [Abstract][Full Text] [Related]
13. Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
Ishii H; Suzaki Y; Miyata Y; Matsui S
Diabetes Ther; 2019 Aug; 10(4):1369-1380. PubMed ID: 31214997
[TBL] [Abstract][Full Text] [Related]
14. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
Yoneda M; Honda Y; Ogawa Y; Kessoku T; Kobayashi T; Imajo K; Ozaki A; Nogami A; Taguri M; Yamanaka T; Kirikoshi H; Iwasaki T; Kurihashi T; Saito S; Nakajima A
BMJ Open Diabetes Res Care; 2021 Feb; 9(1):. PubMed ID: 33593749
[TBL] [Abstract][Full Text] [Related]
15. Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes.
Kakuda H; Kobayashi J; Sakurai M; Takekoshi N
J Clin Med Res; 2019 Jan; 11(1):35-41. PubMed ID: 30627276
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring.
Kawaguchi Y; Sawa J; Kumeda Y
Diabetes Ther; 2020 Dec; 11(12):2945-2958. PubMed ID: 33063270
[TBL] [Abstract][Full Text] [Related]
17. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
[No Abstract] [Full Text] [Related]
19. Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus.
Okada M; Okada M; Nishigami J; Yamaaki N; Furukawa K; Ohyama K; Shimada T; Sai Y
J Pharm Health Care Sci; 2015; 1():26. PubMed ID: 26819737
[TBL] [Abstract][Full Text] [Related]
20. A cross-sectional study of the relationship between quality of life and sleep quality in Japanese patients with type 1 diabetes mellitus.
Ichikawa M; Yamakawa T; Sakamoto R; Takahashi K; Suzuki J; Matsuura-Shinoda M; Shigematsu E; Tanaka S; Kaneshiro M; Asakura T; Kawata T; Yamada Y; Nezu Osada U; Isozaki T; Takahashi A; Kadonosono K; Terauchi Y
Endocr J; 2022 Apr; 69(4):399-406. PubMed ID: 34853196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
